2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2370 CAR-engineered MAIT cells demonstrate potent antileukemic function with distinct metabolic and tissue-hphoming programs

Samuel David Burciaga, Joanne Domenico2, Michael C Yarnell3, Lily Ann Mussallem4, Laurent Gapin, PhD5, Terry Fry, MD6
1 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Chimeric antigen receptor (CAR) T cells are highly effective against B-cell malignancies, but durable remissions remain limited, activity beyond B-cell cancers has been modest, and individualized autologous manufacturing is costly, time-intensive, and variable. Allogeneic, “off-the-shelf”, products could improve consistency and accessibility, but those derived from polyclonal αβ T cells require deletion of the endogenous T-cell receptor (TCR) to prevent graft-versus-host disease, with uncertain effects on fitness and persistence. Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes whose semi-invariant TCR recognizes metabolites presented by monomorphic MR1, limiting alloreactivity while preserving TCR function. MAIT cells also possess innate cytotoxicity and express chemokine receptors associated with trafficking to the bone marrow, liver, lung, and intestine. We hypothesized that MAIT-cell biology would enhance CAR-mediated antitumor function relative to conventional αβ T cells.

Primary human MAIT cells were enriched from healthy-donor peripheral blood based on TRAV1-2 expression, while the matched TRAV1-2-depleted fraction was used to generate conventional αβ T cells. Both populations were activated, transduced with an identical second-generation CD19-directed CAR, and evaluated against CD19-positive Nalm6 leukemia cells. CAR-MAIT cells were successfully expanded and transduced while retaining TRAV1-2 expression and MR1–5-OP-RU tetramer binding, confirming preservation of MAIT lineage identity through manufacturing.

CAR-MAIT cells demonstrated robust cytotoxicity across multiple effector-to-target ratios, with 91% Nalm6 killing at a 1:4 ratio compared with 54% for donor-matched CAR-αβ T cells (n = 1 donor, P = 0.0007). Following antigen stimulation, 82% of CAR-MAIT cells were CD107a⁺ compared with 70% of CAR-αβ T cells, while 50% were IFN-γ⁺ compared with 18% of CAR-αβ T cells (P = 0.0045 and P < 0.0001, respectively). Supernatant profiling after a 16-hour, 1:1 coculture further revealed a distinct effector profile. CAR-MAIT cells produced 6-fold more IL-17A, 2-fold more granzyme A, and 2.5-fold more perforin than donor-matched CAR-αβ T cells, but 14-fold less IL-2 and 3-fold less granzyme B. These reciprocal differences indicate that CAR-MAIT cells are not simply more readily activated, but instead deploy a distinct, lineage-associated repertoire of inflammatory and cytolytic mediators.

To determine whether enhanced CAR-MAIT function was accompanied by greater metabolic activity, we used Single Cell ENergetIc metabolism by profilIng Translation inHibition (SCENITH), a flow cytometry-based method that measures puromycin incorporation as a single-cell readout of metabolically supported protein synthesis. Following tumor coculture, CAR-transduced cells showed increased puromycin incorporation relative to mock-transduced controls in both populations. However, CAR-MAIT cells exhibited 33% lower puromycin incorporation than CAR-αβ T cells despite greater tumor killing, degranulation, and IFN-γ production (P = 0.0030). Thus, the enhanced effector activity of CAR-MAIT cells did not require a corresponding increase in global protein translation.

Single-cell RNA sequencing further demonstrated that CAR-MAIT cells remained transcriptionally distinct from conventional CAR-αβ T cells after ex vivo CAR engineering. CAR-MAIT cells retained canonical MAIT-associated genes, including ZBTB16, KLRB1, inflammatory cytokine receptors, and the chemokine receptors CCR2, CCR5, CCR6, and CXCR6. These findings demonstrate preservation of the innate-like MAIT lineage identity following manufacturing and identify a tissue-homing repertoire that may provide an additional advantage in chemokine-rich tumor microenvironments. Ongoing studies are comparing the in vivo antitumor activity and persistence of CAR-MAIT cells with matched conventional CAR-αβ T cells.

Together, these data show that CAR-MAIT cells exhibit enhanced antileukemic activity, a lineage specific effector repertoire, and lower global protein translation while retaining their innate-like transcriptional identity following manufacturing. These findings support CAR-MAIT cells as a biologically distinct, TCR-intact platform for allogeneic CAR T-cell therapy and motivate evaluation of whether their preserved chemokine-receptor program can improve trafficking and activity in solid tumors.

Samuel David Burciaga: No relevant conflicts of interest to declare.